1. Academic Validation
  2. Structure-Enabled Discovery of a Stapled Peptide Inhibitor to Target the Oncogenic Transcriptional Repressor TLE1

Structure-Enabled Discovery of a Stapled Peptide Inhibitor to Target the Oncogenic Transcriptional Repressor TLE1

  • Chemistry. 2017 Jul 18;23(40):9577-9584. doi: 10.1002/chem.201700747.
Sally McGrath 1 Marcello Tortorici 1 Ludovic Drouin 1 Savade Solanki 1 Lewis Vidler 1 Isaac Westwood 1 Peter Gimeson 2 Rob Van Montfort 3 Swen Hoelder 1
Affiliations

Affiliations

  • 1 The Institute of Cancer Research, Division of Cancer Therapeutics Unit, Cancer Research UK Cancer Therapeutics Unit, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.
  • 2 Malvern Instruments Nordic AB, Vallongatan 1, Uppsala, 752 28, Sweden.
  • 3 Cancer Research (UK) Cancer Therapeutics Unit, Division of Cancer Therapeutics, Division of Structural Biology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.
Abstract

TLE1 is an oncogenic transcriptional co-repressor that exerts its repressive effects through binding of transcription factors. Inhibition of this protein-protein interaction represents a putative Cancer target, but no small-molecule inhibitors have been published for this challenging interface. Herein, the structure-enabled design and synthesis of a constrained peptide inhibitor of TLE1 is reported. The design features the introduction of a four-carbon-atom linker into the peptide epitope found in many TLE1 binding partners. A concise synthetic route to a proof-of-concept peptide, cycFWRPW, has been developed. Biophysical testing by isothermal titration calorimetry and thermal shift assays showed that, although the constrained peptide bound potently, it had an approximately five-fold higher Kd than that of the unconstrained peptide. The co-crystal structure suggested that the reduced affinity was likely to be due to a small shift of one side chain, relative to the otherwise well-conserved conformation of the acyclic peptide. This work describes a constrained peptide inhibitor that may serve as the basis for improved inhibitors.

Keywords

cancer; constrained peptide; inhibitors; protein-protein interactions; structure-based design.

Figures
Products